Ketamine-Derived Drug Approved for Depression Treatment

A new FDA-approved drug that is a form of club drug ketamine is being hailed as a much-needed treatment for depression, but some in workers’ comp are expressing concerns about its safety. The U.S. Food and Drug Administration on Tuesday approved Spravato, a nasal spray form of esketamine. Spravato was approved as a therapy for treatment-resistant depression, defined as inadequate response to treatment with at least two other antidepressant drugs. Spravato is produced by Janssen Pharmaceutical, a division of Johnson & Johnson. Spravato was found to improve symptoms of depression aft...